Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 3/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16329608 | 0.97 | SLC6A1 (0.34) | SLC6A11SLC6A1KIF11KCNH2PBRM1 | |
| SCHEMBL25764740 | 0.97 | SLC6A1 (0.34) | SLC6A11SLC6A1KIF11KCNH2PBRM1 | |
| SCHEMBL27050962 | 0.97 | SLC6A1 (0.34) | SLC6A11SLC6A1KIF11KCNH2PBRM1 | |
| SCHEMBL2820572 | 0.97 | SLC6A1 (0.34) | SLC6A11SLC6A1KIF11KCNH2PBRM1 | |
| SCHEMBL13930001 | 0.94 | SLC6A11 (0.36) | SLC6A11SLC6A1KIF11KCNH2PBRM1 | |
| SCHEMBL26996473 | 0.94 | SLC6A1 (0.33) | SLC6A11SLC6A1KIF11KCNH2 | |
| SCHEMBL26996472 | 0.93 | SLC6A1 (0.33) | SLC6A11SLC6A1 | |
| SCHEMBL17166451 | 0.93 | ALDH1A1 (0.33) | SLC6A11ALDH1A1CYP1A2CYP3A4GAA | |
| SCHEMBL19448739 | 0.92 | SLC6A1 (0.33) | SLC6A11SLC6A1 | |
| SCHEMBL30802594 | 0.92 | SLC6A1 (0.33) | SLC6A11SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-09-25 | — | — | US | claimed |
| EP-2195464-A2 | PRIMERS FOR PCR AMPLIFICATION COMPRISING ABASIC PARTS WITHIN THE PRIMER SEQUENCES | Bioneer Corporation (KR) | 2010-06-16 | — | — | EP | claimed |
| WO-2009045067-A2 | PRIMERS FOR PCR AMPLIFICATION COMPRISING ABASIC PARTS WITHIN THE PRIMER SEQUENCES | BIONEER CORPORATION (KR) | 2009-04-09 | — | — | WO | claimed |
| EP-1506399-A2 | METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS | Aclara BioSciences, Inc. (US) | 2005-02-16 | — | — | EP | claimed |
| WO-2002097112-A2 | CATALYTIC AMPLIFICATION OF MULTIPLEXED ASSAY SIGNALS | ACLARA BIOSCIENCES, INC. (US) | 2002-12-05 | — | — | WO | claimed |
| WO-2002095356-A2 | METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS | ACLARA BIOSCIENCES, INC. (US) | 2002-11-28 | — | — | WO | claimed |
| EP-4623082-A1 | IN VITRO ENZYMATICAL RNA SYNTHESIS | DNA Script (FR) | 2025-10-01 | — | — | EP | disclosed |
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | RACTIGEN THERAPEUTICS (CN) | 2025-09-25 | — | — | US | disclosed |
| WO-2025042899-A2 | METHODS FOR IDENTIFYING COMPOUNDS BINDING TO A TARGET MOLECULE USING MIRROR-IMAGING OF THE TARGET MOLECULE | X-CHEM, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| WO-2024121360-A1 | IN VITRO ENZYMATICAL RNA SYNTHESIS | DNA SCRIPT (FR) | 2024-06-13 | — | — | WO | disclosed |
| US-20240150824-A1 | NUCLEOSIDE-5'-OLIGOPHOSPHATES TAGGED WITH POSTIVIELY-CHARGED POLYMERS, NANOPORES INCORPORATING NEGATIVE CHARGES, AND METHODS AND SYSTEMS USING THE SAME | ROCHE SEQUENCING SOLUTIONS INC (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4330397-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | disclosed |
| EP-4259797-A1 | APTAMER-SIRNA FUSIONS | Apterna Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| WO-2001081630-A2 | TEMPLATE-SPECIFIC TERMINATION IN A POLYMERASE CHAIN REACTION | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001012787-A2 | CHIMERIC DNA/RNA RIBOZYMES CONTAINING PROPANEDIOL | CITY OF HOPE (US) | 2001-02-22 | — | — | WO | disclosed |
| EP-1071821-A1 | METHODS FOR REDUCING NON-SPECIFIC BINDING TO A NUCLEIC ACID PROBE ARRAY | Affymetrix, Inc. (a California Corporation) (US) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999054509-A1 | METHODS FOR REDUCING NON-SPECIFIC BINDING TO A NUCLEIC ACID PROBE ARRAY | AFFYMETRIX, INC. (US) | 1999-10-28 | — | — | WO | disclosed |
| US-5573906-A | Detection of nucleic acids using a hairpin forming oligonucleotide primer and an energy transfer detection system | HOFFMANN-LA ROCHE INC. (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0566751-B1 | DNA detection method | HOFFMANN LA ROCHE (CH) | 1996-01-10 | — | — | EP | disclosed |
| EP-0566751-A1 | DNA detection method | F. HOFFMANN-LA ROCHE AG (CH) | 1993-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250297258-A1 | OLIGONUCLEOTIDE-BASED DELIVERY VEHICLE FOR OLIGONUCLEOTIDES AGENTS AND METHODS OF USE THEREOF | MTREX, DCLRE1B, ADAR | SLC6A11 4520/4885SLC6A1 4633/4885KIF11 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.